{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:49Z","timestamp":1753891309297,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has prevailed globally since November 2021. The extremely high transmissibility and occult manifestations were notable, but the severity and mortality associated with the Omicron variant and subvariants cannot be ignored, especially for immunocompromised populations. However, no prognostic model for specially predicting the severity of the Omicron variant infection is available yet. In this study, we aim to develop and validate a prognostic model based on immune variables to early recognize potentially severe cases of Omicron variant-infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single-center prognostic study involving patients with SARS-CoV-2 Omicron variant infection. Eligible patients were randomly divided into the training and validation cohorts. Variables were collected immediately after admission. Candidate variables were selected by three variable-selecting methods and were used to construct Cox regression as the prognostic model. Discrimination, calibration, and net benefit of the model were evaluated in both training and validation cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six hundred eighty-nine of the involved 2,645 patients were eligible, consisting of 630 non-ICU cases and 59 ICU cases. Six predictors were finally selected to establish the prognostic model: age, neutrophils, lymphocytes, procalcitonin, IL-2, and IL-10. For discrimination, concordance indexes in the training and validation cohorts were 0.822 (95% CI: 0.748-0.896) and 0.853 (95% CI: 0.769-0.942). For calibration, predicted probabilities and observed proportions displayed high agreements. In the 21-day decision curve analysis, the threshold probability ranges with positive net benefit were 0~1 and nearly 0~0.75 in the training and validation cohorts, correspondingly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This model had satisfactory high discrimination, calibration, and net benefit. It can be used to early recognize potentially severe cases of Omicron variant-infected patients so that they can be treated timely and rationally to reduce the severity and mortality of Omicron variant infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1157892","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T04:25:56Z","timestamp":1677644756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of a prognostic model based on immune variables to early predict severe cases of SARS-CoV-2 Omicron variant infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Tianyu","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhong","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lize","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"B1","unstructured":"WHO coronavirus (COVID-19) dashboard 2022"},{"key":"B2","unstructured":"Overview of Variants\/Mutations 2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.587269","article-title":"SARS-CoV-2: Structure, biology, and structure-based therapeutics development","volume":"10","author":"Wang","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J Med Virol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13054-021-03662-x","article-title":"Emerging SARS-CoV-2 variants of concern and potential intervention approaches","volume":"25","author":"Khateeb","year":"2021","journal-title":"Crit Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3201\/eid2809.220613","article-title":"Epidemiology of infections with SARS-CoV-2 omicron BA.2 variant, Hong Kong, January-march 2022","volume":"28","author":"Mefsin","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"B7","unstructured":"Japan's COVID-19 death toll tops 20,000 amid omicron spread Japan: KYODO NEWS; 2022"},{"key":"B8","unstructured":"Propelled by omicron, U.S. death toll from COVID-19 hits 900,000 Los Angeles, Portland: NewsHour; 2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.7281","article-title":"The COVID-19 pandemic rages on for people who are immunocompromised","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01441","article-title":"Immune response, inflammation, and the clinical spectrum of COVID-19","volume":"11","author":"Garcia","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202617","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Le Bert","year":"2021","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00774-w","article-title":"Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects","volume":"19","author":"Zheng","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/joim.13478","article-title":"Advances in the omicron variant development","volume":"292","author":"Vitiello","year":"2022","journal-title":"J Intern Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-022-01105-9","article-title":"Origin, virological features, immune evasion and intervention of SARS-CoV-2 omicron sublineages","volume":"7","author":"Xia","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.3390\/v14122610","article-title":"Evolution of SARS-CoV-2: BA.4\/BA.5 variants continues to pose new challenges","volume":"14","author":"Quadir","year":"2022","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/22221751.2022.2052358","article-title":"SARS-CoV-2 reinfection and COVID-19 severity","volume":"11","author":"Nguyen","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19","volume":"180","author":"Liang","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa963","article-title":"Development and validation of a nomogram for assessing survival in patients with COVID-19 pneumonia","volume":"72","author":"Dong","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26713","article-title":"Development and validation of a nomogram using on admission routine laboratory parameters to predict in-hospital survival of patients with COVID-19","volume":"93","author":"Chen","year":"2021","journal-title":"J Med Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202112_27652","article-title":"Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00327-0","article-title":"Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study","volume":"399","author":"Menni","year":"2022","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28406","article-title":"In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and omicron sub-variants","volume":"95","author":"Abeywardhana","year":"2023","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00471-2","article-title":"Why does the omicron sub-variant spread faster than the original","volume":"602","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3906\/biy-2105-37","article-title":"Pathogenesis and treatment of cytokine storm in COVID-19","volume":"45","author":"Soy","year":"2021","journal-title":"Turk J Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216001","article-title":"Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score","volume":"76","author":"Berenguer","year":"2021","journal-title":"Thorax"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8829674","DOI":"10.1155\/2020\/8829674","article-title":"COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps","volume":"2020","author":"Borges","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70323-7","article-title":"Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis","volume":"13","author":"Wacker","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.04.043","article-title":"Factors associated with mortality in patients with COVID-19. a quantitative evidence synthesis of clinical and laboratory data","volume":"76","author":"Martins-Filho","year":"2020","journal-title":"Eur J Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s15010-021-01602-z","article-title":"State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia","volume":"49","author":"Chong","year":"2021","journal-title":"Infection"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-10814-6","article-title":"The microbial coinfection in COVID-19","volume":"104","author":"Chen","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140965","article-title":"SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition","volume":"130","author":"Sattler","year":"2020","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00992-2","article-title":"COVID-19 and the role of cytokines in this disease","volume":"30","author":"Hasanvand","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214146","article-title":"Cytokine profiling in different SARS-CoV-2 genetic variants","volume":"23","author":"Korobova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2195","article-title":"A systematic meta-analysis of immune signatures in patients with COVID-19","volume":"31","author":"Liu","year":"2021","journal-title":"Rev Med Virol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41421-022-00468-1","article-title":"The omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in shanghai during spring 2022","volume":"8","author":"Ling","year":"2022","journal-title":"Cell Discovery"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05482-7","article-title":"Characterization of SARS-CoV-2 omicron BA.4 and BA.5 isolates in rodents","volume":"612","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1157892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T04:26:05Z","timestamp":1677644765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1157892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2023.1157892"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1157892","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"article-number":"1157892"}}